Innoviva, Inc. (INVA)
D
Pipeline Grade
Financial Position (from SEC Filings)
$603.1M
Cash & Equivalents
$35.3M
Quarterly Burn Rate
$1,633M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (0 Assets)
No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.
Upcoming Catalysts
No upcoming catalysts detected for this company.
Active Clinical Trials (1)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT06794541 | A Study to Evaluate the Safety and Tolerability of Eravacycline in Pediatric Patients Aged 8 to 17 With Complicated Intr... | PHASE2 | Recruiting | 35 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.